French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

Sanofi agreed to buy UK vaccine developer Vicebio Ltd. for as much as $1.6 billion, as it seeks to expand in respiratory ...

Vicebio, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has ...

Vicebio Ltd ("Vicebio" or the "Company"), a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has entered an exclusive, definitive agreement to ...

Sanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...

Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory ...

French pharmaceutical and healthcare company Sanofi has agreed to buy the British biotechnology firm Vicebio for up to $1.6bn ...

Vicebio Ltd, a biopharmaceutical company developing novel vaccines, has entered an exclusive, definitive agreement to be ...

Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...